PrimeRFP SCOUT · Federal Contract Recompete Brief

W58P0521C0008MAB :covid-19: monoclonal antibody therapeutic — Glaxosmithkline LLC

Glaxosmithkline LLC holds $3.0B across 194 federal awards, concentrated at Department of Health and Human Services (HHS). This PIID sits alongside 5 related awards in the incumbent pipeline. The prior award was single-bid — competitive dynamics may favor a challenge. Set-aside status: NONE. PoP ended May 19, 2022 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.

W6qk Acc-Apg Natick

Awarding office

Department of Defense (DOD)

Agency

Glaxosmithkline LLC

Recipient

May 19, 2022

PoP end

$279.9M

Obligated

325412

NAICS

6505

PSC

NONE

Set-aside

1 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Glaxosmithkline LLC — $90

Contract facts

NONE

Contract numberW58P0521C0008

Also listed asW58P05-21-C-0008

AgencyDepartment of Defense (DOD)

Awarding officeW6qk Acc-Apg Natick

IncumbentGlaxosmithkline LLC

UEIFRHTPHMZMX47

NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6505

Place of performanceDURHAM, NC

PoP end (current)May 19, 2022

Obligated$279.9M

:COVID-19: MONOCLONAL ANTIBODY (MAB) THERAPEUTIC SOTROVIMAB is a federal NONE award for Department of Defense (DOD) held by Glaxosmithkline LLC. Estimated value $279.9M ($279.9M obligated). Current period of performance ends May 19, 2022. Last award drew 1 bidder. Place of performance: DURHAM, NC.

:COVID-19: MONOCLONAL ANTIBODY (MAB) THERAPEUTIC SOTROVIMAB

Recompete timing

Public

● Past PoP end (1576 days ago)

Current PoP ended May 19, 2022 (1576 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.

Incumbent footprint

Public record

Glaxosmithkline LLC — $3.0B obligated across 194 awards (firm-wide, all agencies) · lead buyer Department of Health and Human Services (HHS).

% of firm-wide obligated ($3.0B) · all agencies

Department of Health and Human Services (HHS)$3.0B · 100%Department of Defense (DOD)$1.7M · 0%Department of Veterans Affairs (VA)$1.5M · 0%Department of State (DOS)$1.2M · 0%

Open full company profile →

Related awards

Same incumbent

75A50126F61020

TWO-WAY IMMUNOGENICITY TESTING ON EXISTING CLINICAL TRIAL SERA TO IMMUNOGENICITY SUPERIOR…

$493K

Oct 29, 2026

15F06724F0001366

GSK TRAVEL VACCINES

$115K

Dec 31, 2026

15F06726F0000234

GSK VACCINES TERMS AND CONDITIONS REMAIN THE SAME - BPA 15F06722A0000187

$105K

Dec 31, 2026

75A50124F61014

THIS TASK ORDER ESTABLISHES SERVICES FOR H5 PANDEMIC READINESS FOR ACQUISITION OF MEDICAL …

$18.4M

Feb 21, 2027

75A50124F61013

THE PURPOSE OF THIS TASK ORDER IS TO ESTABLISH FILL/FINISH ACTIVITIES FOR ADJUVANT (AS03) …

$15.4M

Feb 21, 2027

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract W58P0521C0008?

W58P0521C0008 (MAB :covid-19: monoclonal antibody therapeutic) is a W6qk Acc-Apg Natick award with an estimated value of $279.9M, currently held by Glaxosmithkline LLC. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

What is W58P05-21-C-0008?

W58P05-21-C-0008 is the dashed form of PIID W58P0521C0008 (MAB :covid-19: monoclonal antibody therapeutic), held by Glaxosmithkline LLC. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.

Which office awarded W58P0521C0008?

W6qk Acc-Apg Natick awarded W58P0521C0008 to Glaxosmithkline LLC.

Who is the incumbent on W58P0521C0008?

Glaxosmithkline LLC is the incumbent with $3.0B across 194 related awards in SCOUT’s public footprint. The current period of performance ends May 19, 2022.

When does Glaxosmithkline LLC’s W58P0521C0008 come up for recompete?

SCOUT tracks a period-of-performance end of May 19, 2022. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Seen enough? Run one full capture cycle on W58P0521C0008 — $90 for 90 days.

This page stays free. Pilot is the live layer: displacement scoring, recompete pipeline, Daily Brief, and SCOUT MCP for 90 days. If you already live in Claude or ChatGPT and only need live search, start MCP Explorer at $29/mo.

Start Pilot — $90

$1/day · one payment · no subscription

Use SCOUT in your AI client — $29/mo

Classify + search inside Claude, ChatGPT, Cursor

Compare plans

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Sep 10, 2026 · refreshed monthlyLatest procurement action Oct 13, 2023